Under Microsoft's "largest ever" investment in Australia, the tech giant is set to partner with Canberra on initiatives spanning cybersecurity, workforce upskilling, and AI development. The new ...

Largest-ever company investment in Australia will expand in-country computing and AI capacity by the end of 2029 Commitment to Government’s Expectations for Data Centres and AI Infrastructure ...

Microsoft Corp. announced its biggest-ever investment in Australia, pledging to spend A$25 billion ($17.9 billion) by the end of 2029 as it pushes deeper into the artificial intelligence market in the ...

Microsoft has said it will invest AU$25 billion (US$18bn) to expand AI and cloud infrastructure and operations in Australia by the end of 2029. Announced by CEO Satya Nadella during Microsoft's AI ...

Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS’s valuation premium is driven by Casdatifan, a ...

The Australian government has struck a major five-year volume sourcing agreement with Microsoft to speed up adoption of artificial intelligence (AI) and cloud technologies across the public sector.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and ...

Arcus Infrastructure Partners will acquire Wifinity, a UK-based internet managed services provider, from LDC and Literacy Capital. Literacy will generate a total expected return of 5.2x MoM, in line ...

Rochdale, England-based WCCTV was formed in 2001 Arcus’ investment will be made via Arcus European Infrastructure Fund 4 SCSp LDC initially invested in WCCTV in 2021 LDC will exit its investment in ...

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...